Bergen, Norway, January 7, 2025 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing the novel, selective AXL kinase inhibitor
bemcentinib for lung cancer announced today that the first patient has been
included in a clinical trial sponsored by the Mays Cancer Center at The
University of Texas Health Science Center at San Antonio (UT Health San
Antonio). The study is led by Josephine A. Taverna, MD, a thoracic oncologist at
the Mays Cancer Center and Associate Professor in the Division of Hematology and
Oncology at UT Health San Antonio.

"Dr. Taverna's research has shown that AXL and JAK-STAT3 work in tandem to
transmit signals promoting tumor growth and metastasis in advanced lung cancer.
We are pleased to see this research advancing into clinical application and
believe this study aligns closely with BerGenBio's strategic focus on addressing
the significant unmet needs of lung cancer patients, including first-line Non
-Small Cell Lung Cancer patients with mutations in the STK11 gene", said Olav
Hellebø, Chief Executive Officer of BerGenBio.

The trial is designed to study BerGenBio's bemcentinib in combination with
pacritinib, which is a JAK2 inhibitor indicated for treatment of the bone marrow
disorder myelofibrosis in patients with platelet counts below 50 x 109/L. It
works by blocking certain growth factors and cytokines. Pacritinib is marketed
in the United States as VONJO® and owned by Swedish Orphan Biovitrum AB (Sobi®)
(STO:SOBI), a specialized international biopharmaceutical company. Bemcentinib
is a first-in-class, selective, oral once-a-day inhibitor of AXL receptor
tyrosine kinase, a promising therapeutic target for serious diseases.

The study will include patients with lung adenocarcinoma, the most common type
of lung cancer in the United States, accounting for approximately 40% of all
lung cancers.The study is funded by a grant from the National Cancer Institute
(NCI) of the National Institutes of Health (NIH).



Contacts

Olav Hellebø, CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

About the Trial (NCT 06516887)

The trial sponsored by the Mays Cancer Center at The University of Texas Health
Science Center at San Antonio is entitled "Study of Bemcentinib plus Pacritinib
in Patients with Advanced adenocarcinoma" is a Phase Ib/II, open-label, single
institution dose-escalation, safety, pharmacokinetics, pharmacodynamic and
efficacy study.  It is anticipated that a total of 44 patients will be enrolled
in the trial.  In the PhIb portion varying doses of bemcentinib and pacritinib
will be studied in combination to determine safety, tolerability and the maximum
tolerated dose.  The Phase II portion of the trial will study the dose(s)
selected in Phase Ib and will assess the overall response rate and progression
free survival of treated patients.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer. The Company is focused on its proprietary
lead candidate, bemcentinib, a potentially first-in-class selective AXL
inhibitor in development for STK11 mutated NSCLC. BerGenBio is based in Bergen,
Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock
Exchange (ticker: BGBIO). For more information, visitwww.bergenbio.com.

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.